usada a n n u a l **REPORT**

2024



• JUSTICE •

MESSAGE FROM THE CEO AND BOARD CHAIR	2
TEAM USADA	4
2024 BY THE NUMBERS	6
GLOBAL CLEAN SPORT ADVOCACY	7
EDUCATION	9
TRUESPORT®	14
SCIENCE, MEDICATIONS, AND SUPPLEMENTS	19
Science Serving Sport	21
Advancing Anti-Doping Science	25
Therapeutic Use Exemptions	27
OLYMPIC & PARALYMPIC ANTI-DOPING PROGRAM	28
2024 Paris Olympic Games Testing Numbers	29
2024 Paris Paralympic Games Testing Numbers	31
Olympic & Paralympic Testing Programs	33
CLIENT SERVICES AND PROGRAMS	36
PFL ANTI-DOPING PROGRAM	39
DOPING CONTROL OPERATIONS	41
TECHNOLOGY	43
RESULTS MANAGEMENT AND INVESTIGATIONS	44
INDEPENDENT AUDITOR'S REPORT	47
	and the second

©2025 USADA. All rights reserved. Permission to reprint or redistribute altered or excerpted materials will be granted on a case-by-case basis. All requests must be made in writing to the U.S. Anti-Doping Agency.

S

Z

ш

Z

T A B L C 0

Ч О

ш

Justice is the bedrock of the anti-doping movement. It's why athletes are willing to make themselves available for testing every hour of every day, check the status of every product they ingest, and submit urine samples to complete strangers. These things can be tedious and uncomfortable, but clean athletes know that their chance of winning depends on their access to a level playing field. Their careers and their legacies depend on justice being upheld.

a a

As anti-doping organizations, our every decision and action must be rooted in fairness so that we create and uphold a system that protects each athlete's rights. When that doesn't happen-when a select few receive special treatment-the foundation of the anti-doping movement starts to crack, and crumble, and eventually fall away entirely.

For USADA, that reality isn't tenable. We know that a strong global anti-doping movement is what athletes need and deserve. That system must both talk the talk and walk the walk when it comes to independence, accountability, and transparency.

Unfortunately, this didn't happen in 2024, when the world learned that China and WADA failed to handle 23 cases in accordance with the rules. That failure meant that 96 medal finishes from the Tokyo and Paris Olympic Games were potentially impacted. Clean athletes might have lost irreplaceable moments and opportunities to athletes who shouldn't have even been competing.

While this failure is devastating, it's equally disturbing to see those in power take no accountability and make no effort to ensure that justice is served. Even the global regulator's hand-picked investigator remarked on how his investigation could not speak to this critical element, noting in the Cottier Report: "The sense of justice or injustice, however, goes far beyond the scope of this investigation."

In the face of injustice, USADA has, and always will, take a stand. We can do nothing less because the athletes playing by the rules deserve far better than a broken system where allegiances matter more than fairness.

While battling for justice alongside our government and international partners, USADA also worked to epitomize fairness and accountability in our own operations. The effort to ensure a level playing field starts with education, and in 2024, we educated nearly 42,000 athletes and other stakeholders through a wide range of modalities. Our strategy included a robust plan for pre-Games education, meaning that all athletes and all credentialed members of the U.S. Olympic and Paralympic Committee received anti-doping education before heading to Paris.

Continued on next page

Our testing plan was equally rigorous, ensuring that all U.S. medalists at the Paris Olympic and Paralympic Games were tested before the Games. For Team USA athletes in individual sports who went on to win gold medals at the Olympic Games, the average number of samples collected pre-Games was 8.3. Along with Pre-Games testing, we maintained our gold-standard testing for all Olympic and Paralympic programs. Over the course of 2024, USADA collected more than 7,550 samples, tested more than 2,850 athletes, and provided doping control at more than 120 events. As a result of both testing and investigations, USADA announced 36 sanctions in 2024.

We also administered anti-doping programs and provided education and testing services to a wide range of sports and sports organizations. For example, in 2024, Powerlifting America, the national federation responsible for promoting powerlifting in the United States, made a significant move to enhance the integrity of the sport by entering into a four-year contract with USADA to manage its anti-doping program. USADA also oversaw the first full year of the Professional Fighters League (PFL) Anti-Doping Program, collecting more than 370 samples and announcing five sanctions. We also continued our work for events like the Boston Marathon and IRONMAN World Championship.

Everything we do, from global advocacy to results management, is rooted in science and research. In 2024, we leveraged this expertise and evidence to issue more than 220 science-initiated testing and analysis recommendations, analyze more than 120 adverse analytical findings and/or other potential anti-doping violations, lead several scientific studies that exonerated innocent athletes, and publish six peer-reviewed scientific papers. We also helped maintain valuable and practical resources, such as Global DRO and the Supplement High Risk List, to help athletes navigate their anti-doping responsibilities.

While we fight to ensure athletes have access to a level playing field across the world, we're also working to ensure that the kids in our own backyards have access to a youth sport environment where they can build the life skills and core values for success on and off the field. Our TrueSport program partners with schools and sports organizations across the country to share out critical resources, and in 2024, we added nine new partners, bringing our youth sport community to more than 21 million people through 94 partnerships. We also hosted our fourth annual symposium on mental health, which garnered more than 1,400 registrants interested in the topic of mental wellness and healthy sport families. TrueSport continues to translate USADA's mission to the next generation, focusing on building healthy and ethical sport culture that represents the best that sport has to offer and that gives young athletes a roadmap for success without sacrificing integrity or wellbeing.

Throughout 2024, our commitment to justice and athlete's rights only grew, fueling our strategic planning and a new mission that will guide us for years to come: We champion athletes to achieve their dreams in a fair and healthy way and to inspire the world. We are forever grateful for the chance to serve clean athletes and ensure they can be the role models the world so desperately needs.

Judi Brown Clarke F2(-1)

Dr. Judi Brown Clarke USADA Board Chair

Travis T. Tygart USADA CEO

S œ 0 $\boldsymbol{\mathcal{O}}$ H υ ш Ľ _ ۵ LL. 0 Ľ ٩ 0 m

The USADA Board of Directors is comprised of experienced individuals who share the ideals and principles behind USADA's mission and core values. Members of the board are independent and thereby cannot serve in any capacity for an organization USADA serves. The Board of Directors advise and support the staff in executing the work of the organization through balanced and informed perspectives. For more information on the USADA Board of Directors, please visit www.USADA.org/board-of-directors.



Judi Brown Clarke, PhD Chair



Kara Goucher Vice Chair



Prof. Timothy Davis Secretary



Lee Carosi Dunn



Alvin M. Matsumoto, MD



Edward J. Merrens, MD



David Plummer, MBA, MEd



Tim Roemer



Cathy Sellers



Stephen Starks



Edwin C. Moses, ScD hc Emeritus Chair A 5 Σ A

LEADERSHIP ш EXECUTIV



Travis T. Tygart



Based in Colorado Springs, Colorado, USADA's

leadership team is responsible for managing and

coordinating comprehensive and independent anti-

doping programs for the U.S. Olympic, Paralympic,

Pan American, and Parapan American movements,

as well as the Professional Fighters League.

John Bobo Chief Executive Officer Chief Innovation Officer Chief Financial Officer Chief Legal & Operations



Sandra Briggs

Jeff Cook Officer

USADA's dedicated and talented team is comprised of more than 100 home-office team members and

field-based Doping Control Officers who work collaboratively to realize the organization's mission to:

Champion athletes to achieve their dreams in a fair and healthy way and to inspire the world.

Matthew Fedoruk, PhD Chief Science Officer

USADA's key initiatives include:

Testing programs

adjudication

Anti-doping education and resources

Science, research, and technology projects

• Results management, investigations, and



Jennifer Royer, PhD Senior Director of TrueSport & Awareness



Scott Bell Assistant Controller

SENIOR LEADERSHIP



Lindsey Stafford Director of Olympic & Paralympic Programs



Daniel Burke Director of Intelligence & Investigations



Shahera Shalabi Director of Human Resources



Juan Caraveo Director of Operations & Special Projects



Allison Wagner Director of Athlete & International Relations



Spencer Crowell Olympic & Paralympic Counsel



Averi Walker Director of Communications



David Goldbach Director of Information Technology



Brent Wood Principal Data Engineer



Tammy Hanson Director of Elite Education



Laura Lewis, PhD **Director of Science**

*Board and staff members include those with USADA at the time of publication.

EDUCATION IMPACT



athletes and stakeholders reached through eLearning, virtual and in-person presentations, individual education sessions, booths, athlete calls, and educational materials.*

> ATHLETES AND ATHLETE SUPPORT PERSONNEL (ASP)

*All audiences represented, including Client Pay education

Before the Olympic Games, we provided anti-doping education to:

Before the Paralympic Games:

S

 \mathbf{n}

S

TRUESPORT

In 2024, TrueSport added

new partners to its network,

bringing the total partners to

Bringing our youth sport community to:

AN INCREASE

9

9

FROM PREVIOUS YEAF

0

ы

m

Q



,100

OLYMPIC & PARALYMPIC MOVEMENT TESTING



RESULTS MANAGEMENT

36)	SANCTIONS IN 2024	ANNOUNCED
	IN 2024	

PFL ANTI-DOPING PROGRAM



SCIENCE

In 2024, the International Paralympic Committee (IPC) became the first International Federation/Major Games Organizer to join Global DRO as a licensee. Athletes and support personnel were able to directly scan QR codes in the Doping Control Stations at the 2024 Paralympic Games in Paris to access medication resources and check their prohibited status in real-time.

SEARCHES ON GLOBAL DRO IN 2024



USADA is committed to advocating for clean sport and clean athletes on a global scale. We unite with stakeholders from around the world, including athletes, governments, and National Anti-Doping Organizations (NADOs), to encourage change in the anti-doping movement so that every athlete is confident they are stepping onto a level playing field and every spectator is confident they are witnessing authentic sport achievements.

CONSISTENCY AND ACCOUNTABILITY IN THE GLOBAL ANTI-DOPING MOVEMENT IN 2024

In April of 2024, reporting by the New York Times and ARD revealed that the positive tests of 23 elite level Chinese swimmers had not been handled according to the rules by China's national anti-doping organization and that the World Anti-Doping Agency (WADA) allowed it to happen. USADA advocated for clean athletes and all athletes' right to a uniform application of the rules created and enforced by WADA, in all countries. This

4

advocacy for athletes' rights in response to the news was consistent with USADA's history of speaking up and taking action to protect the integrity of sport and serve athletes who are dedicated to abiding by anti-doping rules and responsibilities.

Some of the key initiatives on this issue are covered on the next page.

Play the Game

HOLDING WADA ACCOUNTABLE

USADA was one of 18 National Anti-Doping Organizations (NADOs) to issue joint communication to WADA leadership with questions about what the inconsistency in the application of the rules, the lack of enforcement of compliance obligations, and the statements by WADA about this matter mean for athletes and the work of all NADOs. Unfortunately, questions went unanswered.





USADA CEO Travis T. Tygart testified in the Congressional hearing "Examining Anti-Doping Measures in Advance of the 2024 Olympics" alongside Olympic champion swimmers Michael Phelps and Allison Schmitt. The hearing was hosted by The Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce.

RESTORING CONFIDENCE

USADA endorsed the Restoring Confidence to WADA Act, introduced in 2024 by U.S. Senators Marsha Blackburn (R-Tenn.) and Chris Van Hollen (D-Md.) and Representatives John Moolenaar (R-Mich.) and Raja Krishnamoorthi (D-III.). USADA expressed appreciation for this legislation, stating:

"We thank the U.S. Government for protecting the rights of athletes and fair sport by withholding funding from WADA to encourage accountability. We also commend Senator Marsha Blackburn, and the many other champions of clean sport in Congress, for the reintroduction of the Restoring Confidence in the World Anti-Doping Agency Act. Passage of this legislation will be especially important since the U.S. is hosting many major events over the next decade, including the 2026 FIFA World Cup and the 2028 and 2034 Olympic and Paralympic Games."

Education is key to doping prevention, which is why USADA provides education to thousands of athletes, coaches, trainers, medical staff, and other athlete support personnel each year. Through in-person and online education, as well as a multitude of other resources, USADA helps ensure that athletes and support personnel have the tools they need to navigate anti-doping rules and responsibilities, while also understanding the role they play in keeping sport clean.

• IMPACT 41,694 athletes and reached three virtual and i

Ζ

0

-

4

U

D

L.I

athletes and stakeholders reached through eLearning, virtual and in-person

presentations, individual education sessions, booths, athlete calls, and educational materials.*

*All audiences represented, including Client Pay education

FORMS OF EDUCATION	STAKEHOLDERS REACHED
Booths	2,627
Face-to-Face	3,374
eLearning	30,053
Materials	156
Webinars	2,402
DCO First-Time Education	11
Whereabouts Calls	9
Individual Education Sessions	21
Sanctioned Athlete Calls	18
New Athlete Packets	448
Monthly Newsletters	2,500
PFL Onboarding Calls	75
Total	41,694

eLEARNING **STAKEHOLDERS** PROGRAM REACHED Paris Games Rules 1,231 Athlete's Advantage 1,364 **Registered Testing Pool** 1,439 Athlete's Advantage **Clean Athlete Program** Athlete's Advantage 352 **Education Pool** HealthPro Advantage 816 **Clean Sport 101** 69 **ADAMS Athletes** 31 Coach's Advantage 797 Weightlifting Coach's Advantage 1,891 Weightlifting Athlete's Advantage 4.874 NSCA Coach's Advantage 242 Swimming Coach's Advantage 16,672 Triathlon Coach's Advantage 3 Track and Field Coach's Advantage 61 Athletes Returning from Sanction **Client Pay Tutorials** 204

Total

30,053

EDUCATION BY AUDIENCE

Category	Junior	Senior	Coaches	Students	Medical	Other	Total Attendance
Face-to-Face	1,939	672	249	43	74	397	3,374
Webinars	1,572	438	59	24	46	263	2,402
Booths	765	236	237	79	7	1,303	2,627
Materials Only	128	28	N/A	N/A	N/A	N/A	156
Totals	4,404	1,374	545	146	127	1,963	8,559



AROUND THE GLOBE



Ζ

EDUCATIO

2024 MAJOR EVENTS

- Team USA Athlete Summit
 US Figure Skating Team USA
- Coaches; National Championship
- USA Gymnastics Olympic Trials; Senior men's and women's team (trampoline, acro, and rhythmic)
- USA Softball Whereabouts review
- USA Swimming Medical Professionals Seminar; Coaches Clinic; Workshop; Annual Meeting; Olympic Trials
- US Paralympic Nordic Skiing athlete and coach clean sport guidance
- USA Rugby Medical SummitUSA Track and Field Olympic
- USA Track and Field Olympi Trials; Annual Meeting; LA Grand Prix

- USA Paralympic Triathlon Area of Focus for Level I Coaches; Talent ID Camp
- USA Weightlifting and USA Swimming - CBD and THC Webinar
- Pan American Masters Games
- NADO Best Practices Middle East, Jamaica, Mexico
- Blind Soccer National Team
- Army World Class Athlete
- Program (WCAP) Annual Forum
- Badminton Athletic Trainer Education Session
- Rocky Mountain Athletic Conference (RMAC)

2024 MAJOR CONFERENCES

- Caribbean Regional Anti-Doping Organization Education Seminar
- Global Education Conference
- Council of Europe
- Penrose Education Experts and Resource Sharing (PEERS) Group Conference
- Major League Rugby Medical Symposium

2024 EDUCATION PARTNERSHIPS

- National Athletic Trainers Association (NATA)
- Sports Pharmacy Network (SportsRx Network)
- Prevention Strategies at University of North Carolina at Greensboro (UNCG)

Ζ

∢

C

L.

Before the Olympic Games in Paris, we provided anti-doping education to

1,100 athletes and Athlete Support Personnel (ASP), and prior to the Paralympic Games,

327 athletes and ASP received similar

guidance. In addition to live education sessions, athletes and support staff accessed the Paris Games education page on the USADA website, which covered Games-specific rules, instructions for accessing the Paris Games anti-doping eLearning course, our 24/7 hotline information, and TUE guidelines. GAMES EDUCATION PAGE VISITS:

3,156 visits by the end of the Games

PARIS eLEARNING COURSES:

users completed an optional Paris Games eLearning course. member of the USOPC heading to Paris was required to complete anti-doping education. This included coaches, other ASP, and NGB and USOPC staff, for a total of **1,231** ousers educated.

Any credentialed

All athletes attending the Games were added to a USADA testing pool and therefore completed the required anti-doping education prior to heading to Paris.

USADA 2024 ANNUAL REPORT · 12

PARIS GAMES WHEREABOUTS

USADA initiated Whereabouts education calls for any athlete who was going to the Games with 1-2 Whereabouts Failures. This initiative stemmed from our recent athlete perceptions study, which found that 86% of athletes reported feeling anxiety about filing Whereabouts, and these calls were designed to help athletes feel more confident in their filings and reduce anxiety. More than Calls were offered, and feedback from participants reiterated the value of personalized educational offerings. WE SUCCESSFULLY ADVOCATED FOR THE INCLUSION OF ANTI-DOPING INFORMATION IN THE PARIS GAMES STAFF PLAYBOOK.

 \times

ATHLETE PRESENTER PROGRAM & DOPING CONTROL OFFICER (DCO) CONTINUING EDUCATION

Athlete Presenters delivered education to stakeholders at 22 events in 2024. Our seven Athlete Presenters remain eager to engage with the community and share their passion for the clean sport mission.

Doping Control Officers (DCOs) were required to complete continuing education eLearning courses throughout the year. USADA DCOs completed courses on Legal and Results Management, Whereabouts, Unsuccessful Attempts, Athlete Communication, and Sample Collection Personnel Training.

> ATHLETE PRESENTERS ATTENDED:





R E S E A R C H A N D D E V E L O P M E N T

USADA has repeatedly partnered with the University of North Carolina at Greensboro (UNCG) to conduct and assist with research in many areas of antidoping. Recently, USADA and UNCG worked together to develop an innovative evidence-based conceptual model that utilizes the International Standard of Education (ISE) mandatory topics in combination with education modalities to create short, medium, and long-term behavioral outcomes. Also introduced was a changeability matrix for prioritizing anti-doping education, which is a novel approach that will allow anti-doping agencies to allocate resources more efficiently and maximize impact in promoting clean sport. Moreover, the insights on overcoming data collection barriers and optimizing event-based education will be shared with organizations around the world, with the intent to enhance the global effectiveness of clean sport education. STUDENT-ATHLE

Every child deserves the chance to dream big, regardless of their background or circumstances - and sport is a catalyst to help these dreams come true. The culture of sport must evolve to create a space where kids are empowered to explore their potential and pursue their passions. And, our mission is clear: to change the culture of youth sport by providing powerful educational tools to equip young athletes with the resources to build life skills and core values for success - both on and off the field of play. TrueSport's resources focus on Sportsmanship, Character Building & Life Skills, and Clean & Healthy Performance - pillars that help build champions in the sporting arena, and leaders in the game of life.

While the sport system in the U.S. has significant challenges and opportunities, we remain hopeful and steadfast in our belief that change is possible. Investing in the next generation is not just important - it's essential - for the health and development of young people, as well as the health of families and the vitality of communities.

ΙΜΡΑСΤ

In 2024, TrueSport had tremendous IMPACT and INFLUENCE in the youth sport space through our events and programming. In addition, our Athlete Ambassadors, Experts, and Cohort Coaches have INSPIRED and IGNITED a generation of young athletes to pursue their dreams while competing with integrity.

EVENTS & ENGAGEMENTS

We don't just talk the talk - we walk the walk, bringing TrueSport to life with our Athlete Ambassadors, coaches, and experts who inspire future generations through their journeys and research-backed insights. In 2024, we hosted **54 in-person and virtual events** reaching athletes, coaches, family members, and administrators. Highlighted events and collaborations include:

• Kids on Bikes

R

0

5

R

- Camp Susquehannock
- US Soccer Coaches Convention
- US Air Force Academy Sports Camps
- USA Field Hockey Nexus Championships
- LA Bulls Soccer Club
- CSU-Pueblo
- NBA Academy
- USA Korfball



CONTENT & RESOURCES

TrueSport offers a comprehensive suite of resources, including interactive Coaching Certification courses, curriculum-style lessons, videos, supporting publications, and an extensive library of articles, all which provide practical guidance for coaches, parents, and administrators to support young athletes with the life skills and core values that can be learned through sport.

Working alongside experts from a wide range of fields, TrueSport publishes practical and evidence-based content on monthly themes like mental wellness, conflict resolution, and nutrition.

60

TrueSport
 distributed (
 more than

articles through our partner content program.



~4,000

Stakeholders Impacted

TRUESPORT TALKS: MENTAL WELLNESS AND HEALTHY SPORT FAMILIES

MORE THAN

REGISTRANTS

1,400

н К

О 0

ິ

ы

 \supset

Ŷ

Health

Families play a pivotal role in shaping athletes' attitudes, behaviors, and overall perception of mental well-being. By promoting open communication, resilience, and self-care strategies, sport families can mitigate the stressors inherent in competitive athletics while fostering positive mental attitudes.

With this in mind, TrueSport and USADA hosted TrueSport Talks: Mental Wellness and Healthy Sport Families on November 13, 2024, at the U.S. Olympic & Paralympic Museum.

With more than 1,400 registrants, this hybrid event brought together nationally recognized experts in the mental health space to provide workshops on:

- NextGen Sports: Building a Sustainable Future for Tomorrow's Athletes
- Resilient Futures: Parenting for Mental Wellness Through Sport
- Emotionally Fit: Navigating Emotions for Better Mental Health and Sport Performance
- Beyond the Game: Boundaries, Balanced Identity, and Times of Transition in Sport
- Fueling Success: Nurturing the Mind-Body Connection through Sport
- Rekindling Joy: Fun in Sport as Fundamental

Very informative and valuable information that is needed by many organizations, families, and communities. Exceeded my expectations, very informative and relatable information that can be utilized in everyday life.

In addition, **40 student-athletes** from the Colorado Springs community participated in the "Mindset of a TrueSport Champion" program. The 2024 program featured Art with Impact and the National Strength & Conditioning Association, alongside TrueSport Expert and nutritionist, Stephanie Miezin, TrueSport Cohort Coach and mental wellness consultant, Sarah Sutin, and a team of TrueSport Athlete Ambassadors who led attending student-athletes through practical applications of becoming both mentally and physically resilient.

USADA 2024 ANNUAL REPORT · 16

M 0 Ω ິ ы Ŷ

PARTNERSHIPS

WE CAN'T DO THIS WORK ALONE

TrueSport understands the power of partnerships with other likeminded youth sport stakeholders to champion values in sport. By joining forces with National Governing Bodies (NGBs), International Federations, schools, and youth sport organizations, we can amplify our efforts and reach more communities, recognizing that together, we can achieve so much more than we can individually. Through these collaborations and partnerships, we leverage unique channels to engage parents, coaches, and athletes with authentic, sport-based youth development messaging and programs unique to each. The collective strength of our partnerships enables us to create lasting impact and drive meaningful change in the world of youth sports.



AN INCREASE

NEW PARTNERS:

- i360
- Game Plan, powered by BRIDGE
- World Lacrosse
- Kansas City Royals
- California Department of Public Health
- Skyhawks Sports Club
- StarTrack Cycling Club
- YMCA of the Pikes Peak Region
- Colorado Springs School District D11

PARTNER PROGRAM HIGHLIGHTS

KANSAS CITY ROYALS

We were excited to partner with the Kansas City Royals baseball club to feature their Shut out the Stigma campaign and Not Good Enough award-winning documentary at our 2024 TrueSport Talks Symposium. The program challenges parents and coaches to think about how their actions might affect a young athlete's mental health and is in direct alignment with the goals of our TrueSport Talks Symposium.

GAME PLAN

TrueSport partnered with Game Plan to expand access of resources to collegiate athletes in the Game Plan network. In collaboration, we created 6 online modules focused on dietary supplements, hydration, nutrition, and Relative Energy Deficiency Syndrome. These programs empower athletes, coaches, and program administrators to embrace a holistic approach to athlete health and wellbeing. Launched in August 2024, these modules reached nearly 4,000 collegiate athletes.



of the coaches saw behavior change in their athletes with the use of the TrueSport curriculum o-

COHORT FOR CHANGE-

FROM PREVIOUS YEA

The TrueSport Cohort for Change program brings together coaches and youth sport influencers from across the country to help establish best practices and solutions to further the mission of creating a more positive youth sport experience rooted in mental and physical wellness. Through this program, participants help normalize the conversation around mental wellbeing in sport while integrating age-appropriate tools athletes can use to develop and practice mental wellness - all to help foster a healthy, motivational climate.

USADA 2024 ANNUAL REPORT · 17

TrueSport

TrueSpor

• EXPERT PROGRAM

Since its inception in 2020, the TrueSport Expert Program has leveraged the insights and experience of relevant experts, including physicians, psychologists, nutritionists, and social workers, to distinguish TrueSport's content and video resources as reliable, robust, and evidence informed.

THE 2024 TRUESPORT EXPERT PROGRAM INCLUDED:

- BETSY BUTTERICK, Coach and Communication Specialist
- KEVIN CHAPMAN, PhD, Licensed Clinical Psychologist,
- Founder of the Kentucky Center for Anxiety and Related Disorders
- MATT FEDORUK, PhD, Chief Science Officer, USADA
- **DEBORAH GILBOA**, MD, Board Certified Family Physician, Founder of AskDoctorG.com
- NADIA KYBA, MSW, RSW, Registered Social Worker, Founder of NowWhatFacilitation.com
- MICHELE LABOTZ, MD, FAAP, Associate Professor, Tufts University School of Medicine/MaineHealth
- LAURA LEWIS, PhD, Director of Science, USADA
- **STEPHANIE MIEZIN**, MS, RD, CSSD, Registered Dietitian, Director of Nutrition at Kansas City Current
- MELISSA STRENO, PsyD, Licensed Clinical Psychologist, Lantern Psychology
- CHARRON SUMLER, PHD, LPCC, Assistant Director of Sport Psychology and Wellness Services at The Ohio State University
- KRISTEN ZIESMER, MS, RDN, CSSD, LDN, Registered Dietitian, Founder of Elite Nutrition and Performance

T R U E S P O R T A T H L E T E A M B A S S A D O R S

The TrueSport Athlete Ambassadors are incredible role models who inspire the next generation of young athletes by sharing their personal journeys in sport through the lens of the TrueSport values.

THE 2024 TRUESPORT AMBASSADOR TEAM INCLUDED:

- JOE DELAGRAVE, PLY, Wheelchair Rugby
- STEVE EMT, PLY, Wheelchair Curling
- JOSH HARTMAN, Track Sprint Cycling
- TREVON JENIFER, PLY, Wheelchair Basketball
- MANDY MARQUARDT, Track Sprint Cycling
- CHRIS MAZDZER, OLY, Luge
- AMOBI OKUGO, Soccer
- ABBY RAYMOND, Weightlifting
- AARON SCHEIDIES, PLY, Para Triathlon
- MORGAN SHIGO, Track and Field Hammer Throw
- SOPHIA VITAS, OLY, Rowing



A E D I C A T I O N S C I E N C E , A E D I C A T I O N S , A N D S U P P L E M E N T S

Science plays a crucial role in the fight for clean competition by driving innovation and evidence-based decision making. At USADA, science and research inform education strategies, testing, and results management operations, while also enhancing detection and deterrence efforts. Through its drug reference initiatives, USADA provides resources and tools that have a significant impact on the ability of athletes and support personnel to make informed choices about medications and dietary supplements. USADA is also a global leader in anti-doping science, partnering with stakeholders around the world to drive the adoption of athlete-friendly sample collection methods, publish impactful research, and develop surveys that yield quality data to advance meaningful change.

─ 2024 HIGHLIGHTS

USADA SYMPOSIUM

Z V

S

Ω

D

ທ

ш

USADA successfully delivered the 23rd Annual USADA Symposium on Anti-Doping Science titled "Steroid Ab(use): Old problem, new tricks?" in Seattle, Washington.

TESTING & RESULT MANAGEMENT

We leveraged scientific expertise to support testing and result management initiatives, leading to more than **220** science-initiated testing and analysis recommendations, support for more than **120** adverse analytical findings and/or other potential anti-doping violations, several scientific studies that exonerated innocent athletes, and **6** peer-reviewed scientific papers. USADA also helped ensure that Tasso DBS collections could be done for the first time at an Olympic and Paralympic Games in Paris.





COMPLIANCE FOR PARIS

We utilized science and data to maintain a highly strategic risk assessment that supported USADA's near 100% compliance with International Testing Agency (ITA) and International Paralympic Committee (IPC) Pre-Games Testing recommendations, which helped ensure a clean Team USA was sent to Paris.

TASSO+ COLLECTION

In collaboration with Anti-Doping Denmark, USADA collected more than 100 out-of-competition matched capillary and venous blood samples to validate a more athlete friendly blood collection method using the Tasso+ collection device.



SCIENCE SERVING SPORT

USADA is committed to providing athletes and support personnel with the resources and information they need to uphold clean sport, which means providing the most convenient and accurate information on substances and methods through various channels, including a Drug Reference Line direct to USADA staff, Global Drug Reference Online (Global DRO®), and Supplement Connect[®].

DRUG REFERENCE LINE

The USADA Drug Reference Team helps athletes navigate the rules around substances and methods by answering questions online and over the phone. In most cases, USADA was able to provide answers back to athletes or athlete support personnel within 24 hours.



Z ∠ N

Ω

U L

 $- \supset$

ы П

Σ

GLOBAL DRO

Global DRO helps athletes and support personnel identify the prohibited status of medications and ingredients from seven partner and licensee countries: Australia, Canada, Japan, New Zealand, Switzerland, the U.K., and the U.S.

In 2024, the IPC became the first International Federation/Major Games Organizer to join Global DRO as a licensee. Athletes and support personnel were able to directly scan QR codes in the Doping Control Stations at the 2024 Paralympic Games in Paris to access medication resources and check their prohibited status in real-time.



TOP 10 GLOBAL DRO INGREDIENT SEARCHES IN THE U.S. IN 2024:

1	Albuterol & Albuterol 90mcg/actuation Inhalation Aerosol / Salbutamol	4,766
2	Paracetamol/acetaminophen	2,893
3	Creatine	2,562
4	Marijuana	1,898
5	Testosterone	1,674
6	Phenylephrine	1,615
7	lbuprofen	1,417
8	Tramadol	1,408
9	Caffeine	1,253
0	Pseudoephedrine	1,172

you are pregnant or nursing. Supplement Facts

Size 1 Softgel

→ S U P P L E M E N T S -

Dietary supplements are regulated in a post-market fashion, which means that no regulatory body approves the accuracy of the label or safety of the contents before they are sold to consumers. As such, no dietary supplement can be guaranteed to be 100 percent risk-free. While USADA has a long history of working to improve dietary supplement safety, the reality is that the use of dietary supplements can be risky, and that awareness and caution must be exercised when considering their use.

SUPPLEMENT CONNECT

USADA maintains an in-depth resource, called Supplement Connect, to help athletes and support personnel realize, recognize, and reduce the risks from supplements.



Q Search USADA

SUPPLEMENT CONNECT Realize | Recognize | Reduce

HIGH RISK LIST

Within Supplement Connect, USADA also maintains a non-exhaustive High Risk List (HRL) of supplements to provide examples of supplements that pose an anti-doping risk so that athletes can learn to identify, on their own, products that may be risky.

IN 2024:

Z √ N

M N N N



The first table shows the number of products on the HRL by WADA Prohibited List category. Products can have multiple substance classifications since one product may contain multiple prohibited substances or fall under different classifications. For example, higenamine is listed as both a Beta-2 Agonist and a Stimulant.

The second table is the number of products added to the HRL by WADA Prohibited List category (some supplements contained ingredients from multiple categories). Products are added to the HRL if they advertise, or if testing reveals, that they contain substances prohibited in sport.

		0
CLASS	NUMBER	
SO	Non-Approved Substances	21
S1	Anabolic Agents	457
S2	Peptide Hormones, Growth Factors, Related Substances, and Mimetics	39
S3	Beta-2 Agonists	115
S4	Hormone and Metabolic Modulators	129
S5	Diuretics and Masking Agents	1
S6	Stimulants	431
S7	Narcotics	0

CLASS	NUMBER	
SO	Non-Approved Substances	10
S1	Anabolic Agents	78
S2	Peptide Hormones, Growth Factors, Related Substances, and Mimetics	13
S3	Beta-2 Agonists	3
S4	Hormone and Metabolic Modulators	31
S5	Diuretics and Masking Agents	0
S6	Stimulants	73

→ ATHLETE BIOLOGICAL PASSPORT

The Athlete Biological Passport (ABP) program monitors selected biological parameters in urine and blood samples over time that may indirectly reveal effects of doping on the body. The ABP program allows anti-doping organizations to generate individual, longitudinal data sets for each athlete and to look for any fluctuations that may be indicative of the use of performance-enhancing drugs or methods, sometimes long after the drug is no longer directly detectable. This data can also be used to conduct targeted, conventional anti-doping tests on athletes with abnormal characteristics, as well as provide corroborating evidence of doping during an anti-doping rule violation case. The ABP program also serves as a strong doping deterrent.



• RESULTING IN MORE THAN

SPECIFIC TESTING AND

FURTHER ANALYSIS

RECOMMENDATIONS



- Hematological (blood parameters)
- Steroidal (in urine and blood samples)
- Endocrine (in blood samples)

USADA is the Passport Custodian of more than **2,084** athletes, while collaborating with our International Federation (IF) partners to monitor the passports of **637** additional athletes where the IF is the custodian.

A D V A N C I N G A N T I - D O P I N G S C I E N C E

USADA SYMPOSIUM ON ANTI-DOPING SCIENCE

Held in Seattle, Washington, the 23rd Annual USADA Symposium on Anti-Doping Science united more than **85 scientific and medical experts from 28 countries** to discuss anabolicandrogenic steroids (AAS) and other anabolic agents that have taken center stage as the doping agents of choice in many sports globally. Anabolic agents, which come in forms ranging from injectables, to topical creams, to oral preparations, have unfortunately become increasingly common in the anti-aging and wellness industries, as well as illegally marketed in supplements. New designer AAS are also a constant threat, with preclinical and black-market products containing AAS dangerously accessible to consumers.

> While detection methods have grown extremely sensitive in recent years, that sensitivity also makes it even more important that anti-doping agencies can accurately identify contamination scenarios from intentional doping.

As such, the Symposium focused on the direct and indirect detection of more sophisticated anabolic agents, along with strategies to combat unintentional exposure to anabolic agents through different routes of administration. International experts also discussed how to evolve testing and strategies to address the shifting threats posed by anabolic agents.



LARRY D. BOWERS AWARD FOR EXCELLENCE IN ANTI-DOPING SCIENCE

The Symposium also provides the opportunity to recognize and award the achievements of scientists who have made an impact on anti-doping approaches and best practices. USADA was pleased to present the 8th Larry D. Bowers Award for Excellence in Anti-Doping Science to Dr. Jenny Schulze of Anti-Doping Sweden for her pioneering work on the discovery of unique genetic and gender differences in androgen metabolism between individuals, which informed anti-doping and clinical science and led to individualized longitudinal monitoring of steroid biomarkers in the Athlete Biological Passport.

PARTNERSHIP FOR **clean competition**

The Partnership for Clean Competition (PCC) is a nonprofit organization supported by USADA and its other founders in the sports world (USOPC, NFL, MLB, and the PGA Tour) that are devoted to clean sport. Investment in anti-doping science ensures cutting edge research is advancing the anti-doping movement and translating into laboratory and detection improvements. The PCC works to protect the integrity of sport and public health by supporting high quality anti-doping research.

For 16 years, the PCC, USADA, and its partners have been at the forefront of investigating, developing, and implementing new or improved detection methodologies for banned substances and methods, as well as supporting innovative advancements for WADA-accredited antidoping laboratories and anti-doping programs. The PCC has also recently updated its research priorities to adapt to the changing doping landscape.

In 2024, the PCC focused on continuing to fund high impact research and standardizing operations. The PCC also funds postdoctoral research fellowships and working groups to prioritize specific research goals through engagement with global experts to advance specific projects. In addition to financial support, USADA experts support the PCC's daily operations, from leading translational research projects to reviewing grants. Lewis L, Goodrum J, Cai C, Muir T, Boutard K, Capdevielle T, Longo S, Fedoruk M, Miller G. *Application* of micro capillary blood sampling in an anti-doping setting. Drug Test Anal. 2024 Aug;16(8):835-840. doi: 10.1002/dta.3603.

BUTIONS

2

CONT

BLICATION

PU

- Lewis L, Smith M, Boutard K, Fedoruk M, Miller G.
 Comparison of Microcapillary Blood Sampling Devices for Use in Anti-Doping. Drug Test Anal. 2024 Oct 19. doi: 10.1002/dta.3818.
- Sobolevsky T, Fedoruk M, Dellanna F, Geyer H, Ahrens B, Thevis M. Long-Term Excretion of Roxadustat in Urine. Drug Test Anal. 2024 Oct 1. doi: 10.1002/dta.3813.
- Breuer J, Garzinsky AM, Thomas A, Nieschlag E, Kliesch S, Fedoruk M, Geyer H, Thevis M.
 Complementary information concerning the suspected interindividual transmission of GW1516, a substance prohibited in sport, through intimate contact: a case report. Forensic Toxicol. 2024 Jul;42(2):248-254. doi: 10.1007/s11419-024-00689-x.
- Davoren AK, Rulison K, Milroy J, Grist P, Fedoruk M, Lewis L, Wyrick D. Doping Prevalence among U.S. Elite Athletes Subject to Drug Testing under the World Anti-Doping Code. Sports Med Open. 2024 May 20;10(1):57. doi: 10.1186/s40798-024-00721-9.

T H O U G H T L E A D E R S H I P

SELECTED EXPERT COMMITTEE APPOINTMENTS

The members of USADA's Science Team are thought leaders in the global anti-doping science community and welcome the opportunity to collaborate with many international colleagues. This means they lead and contribute to many expert advisory groups, committees, research projects, and conferences worldwide. This ensures that anti-doping science continues to drive the best anti-doping policy and practice to protect athletes and clean sport.

- WADA Health, Medicine, and Research Committee (HMRC)
- WADA Athlete Biological Passport (ABP) Working Group
- WADA Plasma Volume Quantification Working Group
- WADA Hematological Expert Reviewer
- Anti-Doping Advisory Body of the World Aquatics Integrity Unit

- WADA Contaminants Working Group
- International Weightlifting (IWF) Anti-Doping Committee
- ITA Paris Pre-Games Testing Expert Group
- IPC Paris Pre-Games Taskforce
- WADA Global Learning and Development Framework (GLDF) trainer for TUE Administrators & Committee Members

THERAPEUTIC USE EXEMPTIONS REQUESTED T

When legitimate treatment for a diagnosed medical condition contains substances or methods prohibited under the World Anti-Doping Agency (WADA) Prohibited List, athletes may apply for a Therapeutic Use Exemption (TUE). If granted, athletes have permission to use the prohibited treatment in the context of sport. All TUEs are evaluated according to the WADA International Standard for TUEs and the WADA TUE Physician Guidelines, and if approved, are subject to mandatory monitoring for compliance.

2024 HIGHLIGHTS





Reduced processing time to LESS THAN ONE WEEK from the time a TUE is submitted to the TUE Committee for review to the time a decision is reached.

TUE BREAKDOWN BY ATHLETE CLASSIFICATION

ATHLETE CLASSIFICATION	# OF APPLICATIONS	APPROVED	DENIED
Recreational	452	267	34
National/International	112	90	2
TOTAL	564	357	36

REQUESTED TUES Top 5 WADA Prohibited List Categories	NUMBER OF APPLICATIONS
Stimulants	233
Diuretics and Other Masking Agents	72
Glucocorticosteroids	55
Beta-2 Agonists	38
Hormone and Metabolic Modulators	38
APPROVED TUES Top 5 WADA Prohibited List Categories	NUMBER OF Approvals
Stimulants	152
Diuretics and Other Masking Agents	58
Hormone and Metabolic Modulators	31
Glucocorticosteroids	30
Anabolic Agents	19
DENIED TUES Top 5 WADA Prohibited List Categories	NUMBER OF Denials
Anabolic Agents	9
Stimulants	8
Diuretics and Other Masking Agents	5
Beta-2 Agonists	4
Peptide Hormones, Growth Factors, and Other Related Substances	2
Hormone and Metabolic Modulators	2
Cannabinoids	2

* Charts do not include In-Progress, Not-Needed, Incomplete, and Withdrawn TUEs.

OLYMPIC & PARALYMPIC A N T I - D O P I N O P R O G R A M

USADA maintains a gold standard anti-doping program for Olympic, Paralympic, Pan American, and Parapan American sport in the United States. Testing is an integral part of USADA's ability to detect doping and hold accountable those who violate anti-doping rules. Both in-competition (IC) and out-of-competition (OOC) testing are part of an effective anti-doping program that protects clean athletes' rights and a level playing field. No advance notice OOC testing is facilitated by Whereabouts information that athletes are required to submit on an ongoing basis.

2024 PARIS OLYMPIC AND PARALYMPIC GAMES

TESTING NUMBERS

USADA executed a comprehensive testing plan in preparation for the 2024 Olympic and Paralympic Games in Paris. Guided by data and cross-discipline insights, USADA coordinated strategic out-of-competition testing and conducted testing at qualification and trial events. USADA also coordinated with National Governing Bodies to identify the pathway for athletes to be named to Team USA and ensure compliance with all testing recommendations from the International Testing Agency and International Paralympic Committee. The Pre-Games testing strategy required both domestic and international testing, ongoing evaluation of athlete performances, and close collaboration with International Federations to coordinate testing.

2024 PARIS OLYMPIC PRE-GAMES TESTING







-0

2024 PARIS **OLYMPIC** GAMES

TESTING NUMBERS CONTINUED



-0

2024 PARALYMPIC GAMES

TESTING NUMBERS











PROGRAM

Ъ

OLYMPIC & PARALYMPIC TESTING PROGRAMS

Throughout 2024, USADA also maintained gold-standard testing for all U.S. Olympic, Paralympic, Pan American, and Parapan American programs.

HIGHLIGHTS

	6,176 TEST SESSIONS COMPLETED
7,554	2,858 ATHLETES TESTED
TOTAL SAMPLES COLLECTED	124 EVENTS

SAMPLES COLLECTED OUT-OF-COMPETITION (OOC) VS. IN-COMPETITION (IC)

	URINE	BLOOD	SERUM	DBS	TOTALS
000	4,305	1,276	135	121	5,837
IC	1,665	0	4	48	1,717
TOTALS	5,970	1,276	139	169	7,554

SAMPLES COLLECTED BY QUARTER

	URINE	BLOOD	SERUM	DBS	TOTALS
Q1	1,476	2,578	868	1,049	5,970
Q2	358	477	211	230	1,276
Q3	52	51	12	24	139
Q4	45	117	5	2	169
TOTALS	1,931	3,223	1,096	1,304	7,554

SPORT	TOTAL OOC	TOTAL IC	TOTAL TESTS	SPORT	TOTAL OOC	TOTAL IC	TOTAL TESTS
Archery	9	6	15	Paralympic Powerlifting	18	0	18
Artistic Swimming	13	0	13	Paralympic Rowing	23	3	26
Badminton	12	0	12	Paralympic Rugby	16	0	16
Basketball	72	0	72	Paralympic Shooting	2	11	13
Biathlon	76	22	98	Paralympic Snowboard	8	0	8
Bobsled and Skeleton	56	51	107	Paralympic Soccer	15	0	15
Boxing	51	28	79	Paralympic Swimming	146	54	200
Canoe and Kayak	21	20	41	Paralympic Table Tennis	3	0	3
Climbing	19	0	19	Paralympic Taekwondo	8	0	8
Curling	0	4	4	Paralympic Tennis	21	0	21
Cycling	529	143	672	Paralympic Track and Field	248	91	339
Dance Sport	6	0	6	Paralympic Triathlon	114	4	118
Diving	23	21	44	Paralympic Volleyball	19	0	19
Equestrian	10	12	22	Rowing	366	30	396
Fencing	21	0	21	Rugby	77	0	77
Field Hockey	33	0	33	Sailing	6	18	24
Figure Skating	55	12	67	Shooting	0	48	48
Golf	10	0	10	Skateboarding	17	0	17
Gymnastics	99	31	130	Ski Mountaineering	5	0	5
Ice Hockey	24	3	27	Skiing and Snowboarding	129	18	147
Judo	48	20	68	Soccer	92	0	92
Karate	0	18	18	Softball	5	0	5
Luge	20	0	20	Speedskating	143	61	204
Modern Pentathlon	13	8	21	Surfing	5	0	5
Paralympic Alpine Skiing	9	0	9	Swimming	459	246	705
Paralympic Archery	2	8	10	Table Tennis	2	16	18
Paralympic Badminton	2	0	2	Taekwondo	18	4	22
Paralympic Basketball	33	0	33	Tennis	31	0	32
Paralympic Boccia	8	0	8	Track and Field	1687	364	2051
Paralympic Canoe	3	3	6	Triathlon	88	15	105
Paralympic Cycling	207	35	242	Volleyball	90	0	90
Paralympic Equestrian	2	4	6	Water Polo	41	0	41
Paralympic Fencing	6	0	6	Weightlifting	263	227	490
Paralympic Goalball	8	0	8	Wrestling	136	54	190
Paralympic Judo	17	0	17	TOTALS	5,837	1,717	7,554
Paralympic Nordic Skiing	19	4	23				

SAMPLE ANALYSIS

USADA works to determine the optimal analyses for every urine, blood, serum, or DBS sample. All samples are analyzed for a standard list of substances (a basic screen) based on whether it's an in-competition or out-of-competition test. Additional special analyses can be performed to detect specific substances, such as erythropoietin (EPO), growth hormone, and steroids that the body produces naturally. USADA may add special analyses based on factors such as results of the basic screen, intelligence, an athlete's biological passport, sport-specific risks, and requirements by WADA.

In 2024, USADA performed more than **13,000** analyses on Olympic and Paralympic athlete samples. USADA utilizes a variety of different indirect detection methods as part of a comprehensive and strategic testing program, including collections to establish endocrine and blood steroid passports. The graphic below depicts the most common special analyses (by sample type) conducted on USADA samples in 2024, with the size generally corresponding to the frequency.

A Steroid Profile Steroid Esters GRARH GRARH Steroid Esters CIR/IRMS **Blood Steroid Profile** ERAS $\hat{\sim}$ DBS **GH** isoforms

WHEREABOUTS

Whereabouts information is critical to USADA's ability to conduct strategic no advance notice, out-of-competition testing. Athletes in USADA's Registered Testing Pool (RTP) submit quarterly Whereabouts filings and must update USADA on schedule changes. Clean Athlete Program (CAP) participants have limited Whereabouts requirements as part of USADA's strategy to make Whereabouts requirements for athletes proportional to testing. Both groups undergo the same education, including an annual online tutorial, and have multiple ways to communicate their Whereabouts to USADA.

2,680 ATHLETES

(RTP and CAP) provided Whereabouts updates in 2024, and USADA received the following via its Athlete Connect Whereabouts application:

26,495

1,974,008

NUMBER OF UNIQUE LOCATIONS SUBMITTED NUMBER OF WHEREABOUTS UPDATES 5,393

AVERAGE NUMBER OF WHEREABOUTS UPDATES PER DAY


IENT SERVICES And programs

۲

to ta D

USADA provides gold-standard testing services to sports organizations and event organizers worldwide. Various organizations within the Olympic/Paralympic community utilize USADA to conduct their testing, and USADA also seeks to build relationships outside of the Olympic/ Paralympic community to pursue our mission across a diverse range of sports. USADA maintains a cutting-edge anti-doping program by embracing athlete-friendly regulations, pioneering testing methods, and incorporating state-of-the-art technologies. This commitment to innovation is balanced with an unwavering dedication to the core principles of independence, transparency, and accountability.



SAMPLES COLLECTED

OUT-OF-COMPETITION (OOC) VS. IN-COMPETITION (IC)

	URINE	BLOOD	SERUM	DBS	TOTALS
000	758	398	164	12	1,332
IC	860	10	17	28	915
TOTALS	1,618	408	181	40	2,247

SAMPLES COLLECTED

BY QUARTER

	URINE	BLOOD	SERUM	DBS	TOTALS
Q1	438	65	39	7	549
Q2	593	140	62	20	815
Q3	212	37	29	11	289
Q4	375	166	51	2	594
TOTALS	1,618	408	181	40	2,247

2024 HIGHLIGHT: POWERLIFTING AMERICA FULL PROGRAM

Powerlifting America, the national federation responsible for promoting powerlifting in the United States, made a significant move to enhance the integrity of the sport by entering into a fouryear contract with USADA in 2024 to manage its anti-doping program. This comprehensive agreement includes education, inclusion of athletes in a Whereabouts testing pool, out-ofcompetition and in-competition testing, results management, and intelligence and investigations.

\neg E D U C A T I O N

CLIENT EDUCATION TYPE	OPPORTUNITIES	TOTAL AUDIENCE
Booths	997	402
Face-to-Face	8	312
Webinar	12	444
TOTAL	21	1,014

CLIENT EDUCATION TUTORIALS	STAKEHOLDERS REACHED
IRONMAN	19
LifeTime Events	47
Professional Fighters League (PFL)	120
Flag Football	12
Western States	6
TOTAL	204

CLIENTS EDUCATED IN 2024

- New York Road Runners
- IRONMAN®
- Professional Fighters League
- International Brazilian Jiu-Jitsu Federation
- Powerlifting America Classic Sub-Junior/Junior/ Master Nationals
- World Jiu-Jitsu 2024 IBJJF Championships
- LifeTime Grand Prix
- NBA Academy Sessions
- Western States
- Golden Trail Series Webinar
- Lululemon Further Feat
- Football Flag and Tackle National Team



A N T - D O P I N G P R O G R A M

> In 2024, USADA oversaw the first full year of the Professional Fighters League (PFL) Anti-Doping Program. After successfully onboarding all season fighters at the start of the year, out-of-competition testing efforts began, resulting in 251 samples collected from a total of 92 fighters.

In addition to out-of-competition testing, USADA conducted in-competition testing at all PFL Regular Season fights, including the Championships and the PPV Super Fight in Riyadh, Saudi Arabia. ANTI-DOPIN PROGRAM

C

OVERVIEW



SAMPLES COLLECTED OUT-OF-COMPETITION (OOC) VS. IN-COMPETITION (IC)

	URINE	BLOOD	SERUM	TOTALS
000	242	5	4	251
IC	123	0	0	123
TOTALS	365	5	4	374

DRUG REFERENCE RESOURCES AND THERAPEUTIC USE EXEMPTIONS



RESULTS MANAGEMENT



ADVERSE FINDINGS AND OTHER POLICY VIOLATIONS IN 2024

Potential Policy Violations	17
Number of Cases Initiated in 2024 Resulting in a	5
Sanction	
Number of Matters Resulting in No Violation	9
(e.g., due to TUE, permitted method)	
Number of Cases Pending at End of 2024	3

POTENTIAL VIOLATIONS BY CATEGORY

Non-Analytical	1
S1 - Anabolic Agents	10
S2 - Peptide Hormones, Growth Factors, Related	1
Substances, and Mimetics	
S3 - Beta-2 Agonists	1
S4 - Hormone and Metabolic Modulators	5
S5 - Diuretics and Masking Agents	1
S8 - Cannabinoids	1

*Several cases involved more than one Prohibited Substance, Prohibited Method, and/or Anti-Doping Policy Violation

USADA employs more than 70 Doping Control Officers (DCOs) across the country and the world who receive extensive training and evaluation on all aspects of the sample collection process. DCOs are also a resource for athletes and help them properly complete all sample collection paperwork.

BY THE NUMBERS



2024 HIGHLIGHT: OLYMPIC AND PARALYMPIC GAMES

In the lead up to the 2024 Paris Olympic and Paralympic Games, USADA successfully executed a comprehensive and strategic pre-Games testing plan for Team USA. Out-of-competition testing for these athletes peaked in Quarter 2 of 2024, yielding the third-highest testing quarter in USADA's history. For all Olympic and Paralympic trial events prior to Paris, USADA requested that the laboratories expedite sample analysis by team selection deadlines as much as possible to ensure a clean Team USA. USADA also sent 13 representatives, including 12 DCOs, to the Olympic and Paralympic Games in Paris to support doping control operations. USADA staff helped manage doping control stations, sample collection, and the Doping Control Command Center. In addition to supporting doping control efforts in Paris, USADA staff brought home valuable experience, insights, and takeaways that will benefit preparation for the 2028 Games in Los Angeles.

S

0

R

Z O

C

G

Ω

0 0 \bigcirc

• EQUIPMENT INNOVATION

USADA switched to using the InnoVero SafeSystem Blood Kit to ship all blood samples. Compared to previous vessels for blood sample shipments, the SafeSystem Blood Kit has a significantly smaller footprint, allowing for more efficient, consolidated shipping.



USADA conducted a research project for the Tasso+ device with the help of athlete volunteers. This project was a continuation of strategic collaboration between private-sector healthcare partners, athlete representative groups, and USADA to identify a less invasive method for blood collection that will meet international standards for blood analysis.





S

Ζ

 \mathbf{O}

0

R

Ζ

0

C

C

Ω

0

DCO DEVELOPMENT

In a continued effort to fortify our industry-leading field team, USADA provided significant growth and development opportunities for DCOs in 2024. We developed new training resources, analyzed athlete feedback, and provided personalized guidance. Through the creation of Regional Resource Teams, DCOs have a new conduit through which they can communicate and receive resources, compliance guidance, on-call support, and field coaching. These initiatives have led to enhanced testing proficiency, improved athlete experience, and strengthened support for field team members. USADA is invested in using innovative technologies to facilitate efficient, effective, and intelligent anti-doping operations, as well as implementing cutting-edge technologies that streamline and improve the athlete experience.

K E Y 2 O 2 4 A C H I E V E M E N T S

ENHANCED ATHLETE EXPERIENCE

- The Athlete Connect application received nearly 2 million Whereabouts updates covering more than 26,000 locations.
- Athlete Connect introduced new features to help athletes with Whereabouts responsibilities.
- Work continued on new Athlete Connect features to be released in early 2025.

OPERATIONAL EXCELLENCE

- USADA implemented a fully modernized data infrastructure, enabling faster development and deployment of technology.
- We strengthened cybersecurity systems and operations across USADA.
- USADA provided near real-time testing dashboards to more than
 85 partners.

INNOVATION

- USADA was an Enterprise Launch Partner for Perplexity AI, allowing us to learn about large language models (LLMs) on a safe platform.
- We developed apps for realtime DCO alerts and third-party Whereabouts access.
- We worked with Driver AI on the ability to quickly understand legacy code, which sped up development and onboarding of vendors.



USADA is charged with handling the results management and adjudication process for U.S. athletes in Olympic, Paralympic, Pan American, and Parapan American sport. This independence removes the inherent conflict of interest associated with sport organizations trying to both promote and police their sports. USADA's policies and procedures afford a full and fair legal process to athletes and support personnel.

RESULTS MANAGEMENT

36

SANCTIONS ANNOUNCED IN 2024

ADVERSE FINDINGS AND OTHER VIOLATIONS IN 2024

Potential Rule Violations	101
Number of Cases Referred to International	2
Federations or Anti-Doping Organizations	2
Number of Cases Initiated in 2024 Resulting in a	22
Sanction	22
Number of Matters Resulting in No Violation (e.g.,	51
due to TUE, permitted method)	SI
Number of Cases Pending at End of 2024	26

POTENTIAL VIOLATIONS BY CATEGORY	
Non-Analytical	13
SO - Non-Approved Substances	1
S1 - Anabolic Agents	19
S2 – Peptide Hormones, Growth Factors, Related Substances, and Mimetics	5
S3 - Beta-2 Agonists	1
S4 - Hormone and Metabolic Modulators	9
S5 – Diuretics and Masking Agents	22
56 - Stimulants	22
57 - Narcotics	4
58 - Cannabinoids	8
59 - Glucorticoids	2
M1 - Manipulation of Blood and Blood Components	2
M2 - Chemical and Phyiscal Manipulation	2

*Several cases involved more than one Prohibited Substance, Prohibited Method, and/or Anti-Doping Rule Violation

WHEREABOUTS FAILURES

In 2024, USADA continued to provide athletes across the Olympic, Paralympic, and Professional Fighters League (PFL) programs with support in meeting their Whereabouts responsibilities. A Whereabouts Failure (Filing Failure or Missed Test) can result from an athlete's failure to file or update their required Whereabouts information or from an unsuccessful test attempt caused by inaccurate or insufficient Whereabouts information. USADA issued 243 potential Whereabouts Failure notices across the Olympic, Paralympic, and PFL programs, of which 213 were declared to be Whereabouts Failures and 30 were determined not to be Whereabouts Failures upon a detailed review of the circumstances of each attempt and submissions from athletes. USADA also identified opportunities for more proactive athlete support and to that end created a new role to support the Whereabouts program beginning in 2025.

INTELLIGENCE AND INVESTIGATIONS

Under the WADA International Standards for Testing and Investigations (ISTI), USADA and other Anti-Doping Organizations (ADOs) are required to have processes in place that facilitate collection of analytical and non-analytical information. Many of USADA's investigations stem from tips provided through the Play Clean Tip Center. Through this platform, USADA makes available numerous ways to report violations of anti-doping rules. In addition to ensuring that tips can be submitted anonymously, USADA handles all tips in a secure and systematic manner to assess their reliability, relevance, and actionability.







ATHLETES WERE SANCTIONED IN 2024 AS A RESULT OF INTELLIGENCE AND INVESTIGATIONS



Athletes and others can provide information, including photos, to USADA anonymously via text through a service powered by a third-party. In 2024, USADA received **1555** tips through the anonymous texting option.

FINANCIAL STATEMENTS

Statements of Financial Position	
Statements of Activities	
Statement of Functional Expenses -	Year Ended December 31, 2024
Statement of Functional Expenses -	Year Ended December 31, 2023
Statements of Cash Flows	a second and a second as
NOTES TO FINANCIAL STATEMENTS	

1

2

2

3

4

5

6

7

Independent Auditor's Report

Board of Directors United States Anti-Doping Agency Colorado Springs, Colorado

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of United States Anti-Doping Agency, which comprise the statements of financial position as of December 31, 2024 and 2023, and the related statements of activities, functional expenses and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of United States Anti-Doping Agency as of December 31, 2024 and 2023, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Statements" section of our report. We are required to be independent of United States Anti-Doping Agency and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation and maintenance of internal controls relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about United State Anti-Doping Agency's ability to continue as a going concern within one year after the date that these financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and Government Auditing Standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to
 fraud or error, and design and perform audit procedures responsive to those risks. Such
 procedures include examining, on a test basis, evidence regarding the amounts and disclosures
 in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of United States Anti-Doping Agency's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about United States Anti-Doping Agency's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. The schedule of expenditures of federal awards as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards*, is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting not prepare the financial statements or to the financial statements themselves, and other records used to prepare the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the schedule of federal awards is fairly stated in all material respects in relation to the financial statements as a whole.

AUDITOR'S REPORT

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated May 19, 2025, on our consideration of the United States Anti-Doping Agency's internal controls over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal controls over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Agency's internal controls over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Agency's internal controls over financial reporting and compliance.

Forvis Mazars, LLP

Colorado Springs, Colorado May 19, 2025 United States Anti-Doping Agency Statements of Financial Position December 31, 2024 and 2023

	2024	 2023
ASSETS		
Current Assets		
Cash	\$ 921,203	\$ 4,851,745
Accounts receivable, net of allowance;		
2024 - \$4,451 and 2023 – \$3,700	636,587	1,089,218
Grants receivable	308,998	1,928,177
Investments	11,352,652	5,464,523
Supplies	192,427	191,984
Prepaid expenses and other	 700,731	 619,581
Total Current Assets	 14,112,598	 14,145,228
Noncurrent Assets		
Investment in InnoVero, LLC	814,015	782,217
Long-term certificate of deposit	230,002	229,256
Right-of-use assets - operating leases	1,559,295	297,177
Property and equipment, net	 2,187	 10,889
Total Noncurrent Assets	 2,605,499	 1,319,539
Total Assets	\$ 16,718,097	\$ 15,464,767
LIABILITIES AND NET ASSETS		
Current Liabilities		
Accounts payable and other accrued liabilities	\$ 2,619,967	\$ 2,397,495
Deferred revenue and contract liabilities	488,751	359,668
Current maturities of operating lease liabilities	 276,544	 332,497
Total Current Liabilities	 3,385,262	 3,089,660
Noncurrent Liabilities		
Operating lease liabilities, net of current portion	 1,286,025	 11,872
Total Liabilities	 4,671,287	 3,101,532
Net Assets Without Donor Restrictions		
Undesignated	9,296,810	9,613,235
Board-designated	 2,750,000	 2,750,000
Total Net Assets Without Donor Restrictions	 12,046,810	 12,363,235
Total Liabilities and Net Assets	\$ 16,718,097	\$ 15,464,767

United States Anti-Doping Agency Statements of Activities Years Ended December 31, 2024 and 2023

	 2024	 2023
Revenues, Grants and Other Support		
Without Donor Restrictions		
ONDCP federal grant	\$ 14,000,000	\$ 15,250,000
United States Olympic and Paralympic Committee		
(USOPC) contractual agreement	6,600,000	6,600,000
Revenue from testing and other services	2,427,296	8,896,974
Change in equity investment in InnoVero, LLC	18,445	64,627
Net investment return	575,067	362,094
Other loss	 (4,549)	 (7,806)
Total Revenues, Grants and Other Support		
Without Donor Restrictions	 23,616,259	 31,165,889
Expenses		
Program expenses		
Testing services	13,655,539	18,650,007
Results management	2,938,434	2,800,825
Science, research and development and drug reference	2,547,224	2,613,851
Education and awareness	 3,098,866	 3,311,729
Total Program Expenses	22,240,063	27,376,412
General and administrative	 1,692,621	 1,779,173
Total Expenses	 23,932,684	 29,155,585
Change in Net Assets Without Donor Restrictions	(316,425)	2,010,304
Net Assets Without Donor Restrictions, Beginning of Year	 12,363,235	 10,352,931
Net Assets Without Donor Restrictions, End of Year	\$ 12,046,810	\$ 12,363,235

United States Anti-Doping Agency Statement of Functional Expenses Year Ended December 31, 2024

			Prog	ram Services				Support Services	
	 Testing	Results anagement	Re Deve	Science, search and elopment and g Reference	ucation and wareness	 Total Program	-	eneral and ministrative	 Total Expenses
Salaries and benefits Sample collection and analysis Professional services Travel Information technology Occupancy, utilities and administrative expenses Offices expenses Conferences, conventions	\$ 4,036,687 4,189,891 295,050 1,565,647 2,620,970 902,928 21,803	\$ 1,856,057 226 864,446 64,945 118,162 14,318 10,966	\$	1,451,483 42,000 589,346 65,669 158,283 21,477 42,798	\$ 2,122,583 490,617 130,485 48,058 35,795 51,048	\$ 9,466,810 4,232,117 2,239,459 1,826,746 2,945,473 974,518 126,615	\$	1,048,022 225,119 110,884 46,394 220,727 27,572	\$ 10,514,832 4,232,117 2,464,578 1,937,630 2,991,867 1,195,245 154,187
and meetings Other expenses Total expenses	\$ 229 22,334 13,655,539	\$ 3,358 5,956 2,938,434	\$	172,381 3,787 2,547,224	\$ 126,004 94,276 3,098,866	\$ 301,972 126,353 22,240,063	\$	4,492 9,411 1,692,621	\$ 306,464 135,764 23,932,684

See Notes to Financial Statements

INDEPENDENT AUDITOR'S REPORT ------

United States Anti-Doping Agency Statement of Functional Expenses Year Ended December 31, 2023

			Prog	ram Services					Support Services		
	 Testing	Results inagement	Re Deve	Science, search and elopment and g Reference		ication and wareness	 Total Program	-	eneral and ministrative		Total Expenses
Salaries and benefits Sample collection and analysis Professional services Travel Information technology Occupancy, utilities and administrative expenses	\$ 5,010,626 6,487,935 543,900 2,009,287 3,581,576 927,848	\$ 2,079,456 528,425 86,254 72,300 19,912	\$	1,557,279 41,253 594,987 66,469 71,983 27,028	\$	2,192,994 561,362 153,901 72,248 31,337	\$ 10,840,355 6,529,188 2,228,674 2,315,911 3,798,107 1,006,125	\$	1,123,057 217,399 81,201 78,572 224,697	\$	11,963,412 6,529,188 2,446,073 2,397,112 3,876,679 1,230,822
Offices expenses Conferences, conventions and meetings Other expenses Total expenses	 32,657 17,487 <u>38,691</u> 18,650,007	\$ 7,315 2,304 4,859 2,800,825	\$	26,011 218,193 10,648 2,613,851	¢	24,355 191,086 84,446 3,311,729	\$ 90,338 429,070 138,644 27,376,412	\$	23,418 9,721 21,108 1,779,173	•	113,756 438,791 159,752 29,155,585

See Notes to Financial Statements

INDEPENDENT AUDITOR'S REPORT ------

United States Anti-Doping Agency Statements of Cash Flows Years Ended December 31, 2024 and 2023

	2024		 2023
Operating Activities			
Change in net assets	\$	(316,425)	\$ 2,010,304
Items not requiring (providing) cash			
Depreciation and amortization		8,702	11,721
Noncash operating lease expense		340,291	333,992
Net realized and unrealized losses		(183,624)	(217,696)
Change in equity investment in InnoVero, LLC		(18,445)	(64,627)
Changes in			
Accounts receivable		452,631	(67,156)
Grants receivable		1,619,179	1,216,120
Supplies		(443)	65,989
Prepaid expenses and other		(94,503)	129,056
Accounts payable and other accrued liabilities		222,472	(453,636)
Operating lease liability		(384,209)	(373,270)
Deferred revenue and contract liabilities		129,083	 142,067
Net Cash Provided by Operating Activities		1,774,709	 2,732,864
Investing Activities			
Purchase of investments		(16,048,608)	(4,594,985)
Proceeds from sale of investments		10,343,357	 1,022,712
Net Cash Used in Investing Activities		(5,705,251)	 (3,572,273)
Decrease in Cash		(3,930,542)	(839,409)
Cash, Beginning of Year		4,851,745	 5,691,154
Cash, End of Year	\$	921,203	\$ 4,851,745
Supplemental Cash Flow Information Cash paid for amounts included in the measurement of lease liabilities			
Operating cash flows from operating leases ROU assets obtained in exchange	\$	397,151	\$ 389,694
for new operating lease liabilities	\$	1,602,409	\$ -

United States Anti-Doping Agency Notes to Financial Statements December 31, 2024 and 2023

Note 1. Nature of Operations and Summary of Significant Accounting Policies

Nature of Operations

United States Anti-Doping Agency (the Agency) began operations October 1, 2000. The Agency is responsible for testing, education, research and adjudication for U.S. Olympic and Paralympic athletes, Pan American Games, and the Ultimate Fighting Championship. During 2023, the Ultimate Fighting Championship contract ended. The Agency is also responsible for enhancing research efforts and promoting educational programs to inform athletes of the rules governing the use of performance-enhancing substances, the ethics of doping and its harmful health effects.

The Agency also receives a federal grant from the Office of National Drug Control Policy. The grant is renewable annually and is from January 1, 2024 through December 31, 2024. The Agency has received notification of award renewal for 2025 with terms similar to 2024.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues, expenses, gains, losses and other changes in net assets during the reporting period. Actual results could differ from those estimates.

Cash

At December 31, 2024, the Agency's cash accounts exceeded federally insured limits by approximately \$647,000. Uninvested cash included in investment accounts are not considered to be cash for financial reporting purposes.

Accounts Receivable

Accounts receivable are stated at the amount of consideration from customers, of which the Agency has an unconditional right to receive plus any accrued and unpaid interest. The Agency provides an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information and existing economic conditions. Delinquent receivables are written off based on individual credit evaluation and specific circumstances of the customer.

Contract Assets

Contract assets are recorded when the Agency has a right to consideration in exchange for goods or services that the Agency has transferred to the customer.

Investments

The Agency measures securities, other than investments that qualify for the equity method of accounting, at fair value.

Net Investment Return

Investment return includes dividend, interest, and other investment income; realized and unrealized gains and losses on investments carried at fair value; and realized gains and losses on other investments, less external and direct internal investment expenses. Gains and losses on the sale of securities are recorded on the trade date and are determined using the specific identification method.

United States Anti-Doping Agency Notes to Financial Statements December 31, 2024 and 2023

Supplies

Supplies consist of drug testing kits and other doping control supplies and are valued at the lower of cost (first-in, first-out method) or net realizable value.

Property and Equipment

Property and equipment are recorded at cost, less accumulated depreciation. Depreciation and amortization are calculated using the straight-line method over the following estimated useful lives:

Computer equipment and software	3 – 5 years
Furniture, fixtures and office equipment	5 – 7 years
Website development	3 years
Lab equipment	5 years

Leasehold improvements are amortized over the term of the leases or the estimated lives of the improvements, whichever is shorter.

Deferred Revenue and Contract Liabilities

Deferred revenue includes revenues received and deferred and is recognized over the periods to which the fees relate. Contract liabilities represent the Agency's obligation to transfer goods or services to a customer when consideration has already been received from the customer.

Net Assets

Net assets, revenues, gains and losses are classified based on the existence or absence of donor- or grantorimposed restrictions.

Net assets without donor restrictions are available for use in general operations and not subject to donor or certain grantor restrictions. The governing board has designated, from net assets without donor restrictions, net assets for research and contingencies.

Net assets with donor restrictions are subject to donor- or certain grantor-imposed restrictions. The Agency does not have any donor-restricted net assets.

Federal Grants and Grants Receivable

Support funded by grants is recognized as the Agency performs the contracted services or incurs outlays eligible for reimbursement under the grant agreements. Expenses incurred but not reimbursed are recorded as grants receivable. Grant activities and outlays are subject to audit and acceptance by the granting agency and, as a result of such audit, adjustments could be required. The value recorded for the federal grants is recognized as follows:

Value Recognized
cognized until the gift becomes unconditional, a donor-imposed barrier is met

United States Anti-Doping Agency Notes to Financial Statements December 31, 2024 and 2023

United States Olympic and Paralympic Committee (USOPC) Contractual Agreement and Testing Services Revenue

USOPC contractual agreement and testing services revenue is recognized as the Agency satisfies performance obligations under its contracts. Revenue is reported at the estimated transaction price or amount that reflects the consideration to which the Agency expects to be entitled in exchange for providing goods or services. The Agency determines the transaction price based on standard charges for goods and services provided. The Agency determines its estimates implicit price concessions based upon historical experience.

Income Taxes

The Agency is exempt from income taxes under Section 501(c)(3) of the Internal Revenue Code and a similar provision of state law. However, the Agency is subject to federal income tax on any unrelated business taxable income.

Functional Allocation of Expenses

The costs of supporting programs and activities have been summarized on a functional basis in the statements of activities. The statements of functional expenses present the natural classification detail of expenses by function. Certain costs have been reasonably allocated among the program and management and general categories based on the percentage of effort, percentage of utilization and other methods.

Revision

Certain immaterial revisions have been made to Note 9 of the Agency's financial statements to disclose contract liabilities. This revision had no impact on the related financial statement line items.

Note 2. Disclosures About Fair Value of Assets and Liabilities

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements must maximize the use of observable inputs and minimize the use of unobservable inputs. There is a hierarchy of three levels of inputs that may be used to measure fair value:

Level 1 Quoted prices in active markets for identical assets or liabilities

- Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities
- Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities

United States Anti-Doping Agency Notes to Financial Statements December 31, 2024 and 2023

Recurring Measurements

The following tables present the fair value measurements of assets recognized in the accompanying statements of financial position measured at fair value on a recurring basis and the level within the Topic 820 fair value hierarchy in which the fair value measurements fall at December 31, 2024 and 2023:

		2024						
				Fair Va	lue Meas	urement	s Using	
	F	air Value	M	oted Prices n Active arkets for Identical Assets (Level 1)	Ot Obse Inp	ficant her rvable uts rel 2)	Unobs Inp	ificant ervable outs vel 3)
Equity mutual funds								
Large-cap	\$	951,844	\$	951,844	\$	-	\$	-
International	*	497,752	Ŧ	497,752	Ŧ	-	Ŧ	-
Small- and mid-cap		141,353		141,353		-		-
Other mutual funds								
Fixed income bonds		641,207		641,207		-		-
Real estate		116,857		116,857		-		-
Money market		8,398,294		8,398,294		-		-
Certificates of deposit								
Short-term		499,845		-	2	99,845		-
Long-term		230,002		-	2	230,002		-
		44 477 454						
Coop and coop aquivalanta		11,477,154 105,500						
Cash and cash equivalents		105,500						
Subtotal Investments		11,582,654						
Less long-term investments		230,002						
Short-term investments	\$	11,352,652						

United States Anti-Doping Agency Notes to Financial Statements December 31, 2024 and 2023

			2023 Fair Value Measurements Using					
	F	air Value	ii Mi	oted Prices n Active arkets for dentical Assets Level 1)	Signi Ot Obse Inp	ficant her rvable outs rel 2)	Signi Unobs Inp	ficant ervable outs vel 3)
Equity mutual funds								
Large-cap	\$	805,914	\$	805,914	\$	-	\$	-
International		576,296		576,296		-		-
Small- and mid-cap		131,560		131,560		-		-
Other mutual funds								
Fixed income bonds		579,451		579,451		-		-
Real estate		66,394		66,394		-		-
Money market		2,128,673		2,128,673		-		-
Certificates of deposit								
Short-term		917,025		-		917,025		-
Long-term		229,256		-	2	229,256		-
		5,434,569						
Cash and cash equivalents		259,210						
Subtotal Investments		5,693,779						
Less long-term investments		229,256						
Short-term investments	\$	5,464,523						

Following is a description of the valuation methodologies and inputs used for assets and liabilities measured at fair value on a recurring basis and recognized in the accompanying statements of financial position, as well as the general classification of such assets and liabilities pursuant to the valuation hierarchy. There have been no significant changes in the valuation techniques during the years ended December 31, 2024 and 2023.

Investments

Where quoted market prices are available in an active market, securities are classified within Level 1 of the valuation hierarchy. Level 1 securities include large-cap, small- and mid-cap, and international equity mutual funds; and real estate and fixed income bond mutual funds. If quoted market prices are not available, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. These are considered Level 2 securities are classified within Level 3 of the hierarchy. Currently, the Agency does not have Level 3 securities.

United States Anti-Doping Agency Notes to Financial Statements December 31, 2024 and 2023

Note 3. Investment in InnoVero, LLC

On February 7, 2019, InnoVero, LLC (InnoVero) was incorporated and on December 31, 2019, the partnership agreement was created and InnoVero became the manufacturer of anti-doping products and practices for athletes. The Agency has a 50% interest in InnoVero at December 31, 2024 and 2023. The investment is accounted for under the equity method. The net income and net loss of InnoVero will be allocated amongst the Agency and the other investor based upon the ownership interest. Financial position and results of operations of the investee are summarized as follows:

	2024	2023
Current assets	\$ 972,043	\$ 1,163,700
Noncurrent assets	2,636,067	2,618,494
Total assets	3,608,110	3,782,194
Current liabilities	142,299	351,680
Members' equity	\$ 3,465,811	\$ 3,430,514
Revenues	\$ 2,035,541	\$ 2,251,699
Net income	\$ 36,889	\$ 129,254

The Agency recognized income on the investment in equity investee of \$18,445 and \$64,627 at December 31, 2024 and 2023, respectively. The investment balance was \$814,015 and \$782,217 at December 31, 2024 and 2023, respectively.

Note 4. Property and Equipment

Property and equipment at December 31, 2024 and 2023 consists of:

	 2024	 2023
Computer equipment and software	\$ 577,244	\$ 577,244
Furniture, fixtures and office equipment	64,275	64,275
Leasehold improvements	80,025	80,025
Lab equipment	 116,599	 116,599
	838,143	838,143
Less accumulated depreciation and amortization	 (835,956)	 (827,254)
Total property and equipment, net	\$ 2,187	\$ 10,889

....

~~~~

United States Anti-Doping Agency Notes to Financial Statements December 31, 2024 and 2023

#### Note 5. Leases

#### Accounting Policies

The Agency determines if an arrangement is a lease or contains a lease at inception. Leases result in the recognition of ROU assets and lease liabilities on the statements of financial position. ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease, measured on a discounted basis. The Agency determines lease classification as operating or finance at the lease commencement date.

The Agency accounts for lease and nonlease components separately. The Agency allocates the consideration to the lease and nonlease components using their relative standalone values. In addition, the Agency applies a portfolio approach to effectively account for the operating lease ROU assets and liabilities.

At lease commencement, the lease liability is measured at the present value of the lease payments over the lease term. The ROU asset equals the lease liability adjusted for any initial direct costs, prepaid or deferred rent, and lease incentives. The Agency has made a policy election to use a risk-free rate (the rate of a zero-coupon U.S. Treasury instrument) for the initial and subsequent measurement of all lease liabilities. The risk-free rate is determined using a period comparable with the lease term.

The lease term may include options to extend or to terminate the lease that the Agency is reasonably certain to exercise. Lease expense is generally recognized on a straight-line basis over the lease term.

The Agency has elected not to record leases with an initial term of 12 months or less on the statements of financial position. Lease expense on such leases is recognized on a straight-line basis over the lease term.

#### Nature of Leases and Quantitative Disclosures

Right-of-use assets, operating leases as of December 31, 2024 and 2023 consist of:

|                                            | Asset |                    |    |                   |  |  |
|--------------------------------------------|-------|--------------------|----|-------------------|--|--|
|                                            | 2024  |                    |    | 2023              |  |  |
| Office space lease (A)<br>Copier lease (B) | \$    | 1,552,562<br>6,733 | \$ | 270,569<br>26,608 |  |  |
| Right-of-use assets                        | \$    | 1,559,295          | \$ | 297,177           |  |  |

Lease liabilities as of December 31, 2024 and 2023 consist of:

|                                            | Liability |                        |    |                      |  |
|--------------------------------------------|-----------|------------------------|----|----------------------|--|
|                                            |           | 2024                   |    | 2023                 |  |
| Office space lease (A)<br>Copier lease (B) | \$        | 1,550,697<br>11,872    | \$ | 312,622<br>31,747    |  |
| Less current portion                       |           | 1,562,569<br>(276,544) |    | 344,369<br>(332,497) |  |
| Lease liabilities, net of current portion  | \$        | 1,286,025              | \$ | 11,872               |  |

United States Anti-Doping Agency Notes to Financial Statements December 31, 2024 and 2023

- (A) The Agency has entered into an operating lease agreement for office space. During 2024, the existing lease that expired in October 2024 and a new lease was entered into that went into effect November 1, 2024. Under the terms of the 2024 lease agreement, the Agency will pay escalating monthly payments through October 2029 and have unlimited use of the space for that period of time. At lease inception, the lease liability is measured at the present value of the lease payments over the lease term. The Agency used a 3% imputed interest rate to calculate the present value of future cash flows in relation to the lease liability. The Agency recognized \$332,678 and \$329,860 in operating lease expense related to these leases in 2024 and 2023, respectively.
- (B) The Agency has an operating lease agreement for several copiers. During 2020, the existing lease that was set to expire in November 2021 was terminated and a new lease was entered into. Under the terms of the 2020 agreement, the Agency will pay \$1,713 in monthly payments through July 2025 and will have unlimited use of the copiers for that period of time. At lease inception, the lease liability is measured at the present value of the lease payments over the lease term. The Agency used a 3% imputed interest rate to calculate the present value of future cash flows in relation to the lease liability. The Agency recognized \$34,042 and \$29,331 in operating lease expense related to this lease in 2024 and 2023, respectively.

Future undiscounted cash flows for operating leases at December 31, 2024 are as follows:

| 2025                                     | \$<br>358,757   |
|------------------------------------------|-----------------|
| 2026                                     | 326,258         |
| 2027                                     | 337,444         |
| 2028                                     | 367,274         |
| 2029                                     | <br>335,580     |
|                                          |                 |
| Total future undiscounted lease payments | 1,725,313       |
| Less imputed interest                    | <br>(162,744)   |
|                                          |                 |
|                                          | \$<br>1,562,569 |

#### Note 6. Liquidity

The Agency receives its funding from three key sources; a federal government grant, a contract with the U.S. Olympic and Paralympic Committee and contracted anti-doping services it provides to a variety of customers. There are no donor restrictions on funding.

# AUDITOR'S REPORT

United States Anti-Doping Agency Notes to Financial Statements December 31, 2024 and 2023

As of December 31, 2024 and 2023, the following table shows the total financial assets held by the Agency that could readily be made available within one year of the statements of financial position date to meet general and operating expenses:

|                                                                            | 2024 |            | 2023 |            |
|----------------------------------------------------------------------------|------|------------|------|------------|
| Cash                                                                       | \$   | 921,203    | \$   | 4,851,745  |
| Accounts receivable                                                        |      | 636,587    |      | 1,089,218  |
| Grants receivable                                                          |      | 308,998    |      | 1,928,177  |
| Investments convertible to cash in the next 12 months                      |      | 11,352,652 |      | 5,464,523  |
| Financial assets available to meet general<br>expenditures within one year | ¢    | 13,219,440 | ¢    | 13,333,663 |
| expenditures within one year                                               | - Þ  | 13,219,440 | ð    | 13,333,003 |

The Agency has board-designated net assets, which are included in investments, for various purposes more fully described in Note 7. These could be made available to use within one year, as determined by the board, if necessary. Accordingly, these assets have been included in the quantitative information above.

The Agency regularly monitors liquidity required to meet its operating needs. Its liquidity strategy is to maintain sufficient liquid assets to cover 90 days of operations, maintain a high level of liquidity in all investments and operate as guided by the board approved budget.

#### Note 7. Board-Designated Net Assets Without Donor Restrictions

The Board has designated net assets for the following purposes:

|                           | <br>2024                     |    | 2023                   |  |
|---------------------------|------------------------------|----|------------------------|--|
| Research<br>Contingencies | \$<br>1,000,000<br>1,750,000 | \$ | 1,000,000<br>1,750,000 |  |
|                           | \$<br>2,750,000              | \$ | 2,750,000              |  |

United States Anti-Doping Agency Notes to Financial Statements December 31, 2024 and 2023

#### Note 8. USOPC Contract

The Agency has an agreement with the United States Olympic and Paralympic Committee (USOPC) to conduct a drug testing and anti-doping program for athletes in the Olympic, Paralympic and Pan American Games. During 2022, a new agreement was entered into through December 31, 2028. Support funded by the USOPC is recognized as the Agency performs the contracted services. Revenue received from the USOPC for the years ended December 31, 2024 and 2023 was \$6,600,000, of which \$419,781 and \$383,929 was included in accounts receivable at December 31, 2024 and 2023, respectively. To mitigate the perceived conflict of interest between the Agency and the New Era ADR, Inc. in 2023 and the American Arbitration Association (AAA) in 2022 or the Court of Arbitration for Sport (CAS), which provides arbitration services for cases brought forth by the Agency, the USOPC directly pays all arbitration fees and expenses incurred by these entities up to a cap of \$500,000 in 2024 and 2023. During 2024 and 2023, the USOPC directly paid arbitration costs to these entities of \$228,859 and \$130,678, respectively. If the arbitration expenses incurred are less than the cap, then the excess up to the cap is remitted to the Agency, which is included in the contract amount above. If the arbitration expenses incurred are more than the cap, then the excess is paid to the USOPC. At December 31, 2024 and 2023, there were excess amounts owed to the Agency.

#### Note 9. Revenue from Contracts with Customers

#### USOPC, Testing and Other Services Revenue

Performance obligations are determined based on the nature of the goods or services provided by the Agency in accordance with the contract. Revenue for performance obligations satisfied over time is recognized ratably over the period based on time elapsed. The Agency believes this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation.

#### Transaction Price and Recognition

The Agency determines the transaction price based on standard charges for goods and services provided reduced by implicit price concessions provided to customers. The Agency determines its estimate of implicit price concessions based on its historical collection experience with this class of customers.

The Agency has determined that the nature, amount, timing and uncertainty of revenue and cash flows are affected by the following factors:

- Payers (for example, customer and others) that have different reimbursement and payment methodologies
- Geography of the service location

For the year ended December 31, 2024, the Agency recognized revenue from goods and services that transfer to the customer over time.

United States Anti-Doping Agency Notes to Financial Statements December 31, 2024 and 2023

#### **Contract Balances**

The following table provides information about the Agency's receivables and liabilities from contracts with customers:

|                                         | 2024 |           | 2023 |           |
|-----------------------------------------|------|-----------|------|-----------|
| Accounts receivable, beginning of year  | \$   | 1,089,218 | \$   | 1,022,062 |
| Accounts receivable, end of year        | \$   | 636,587   | \$   | 1,089,218 |
| Contract liabilities, beginning of year | \$   | 359,668   | \$   | 217,601   |
| Contract liabilities, end of year       | \$   | 488,751   | \$   | 359,668   |

#### Note 10. Employee Benefit Plan

The Agency maintains a 401(k) benefit plan covering all employees who meet the eligibility requirements. The Agency makes contributions at its discretion. The Agency's contributions to the plan were \$463,827 and \$491,339 for the years ended December 31, 2024 and 2023, respectively.

#### Note 11. Significant Commitments, Estimates and Concentrations

Accounting principles generally accepted in the United States of America require disclosure of certain significant estimates and current vulnerabilities due to certain concentrations. Those matters include the following:

#### **Revenue Concentration**

The Agency received 87% and 92% of its support during 2024 and 2023, respectively, from three organizations. As discussed in Note 8, the Agency has a contract with the USOPC (one of the three major organizations) through 2028.

#### **Equipment Grant**

Effective September 9, 2008, the Agency, as grantor, entered into a grant agreement with Sports Medicine Research and Testing Laboratory (the Laboratory). Under the terms of this grant agreement, the Agency will grant a piece of equipment with a cost of \$71,750 and now fully depreciated to the Laboratory. The Laboratory must use the equipment of purposes that fit within the Agency's mission and must report the detail of testing performed with the equipment to the Agency each year. The Agency would have the right to take back the equipment if either of these requirements was not met. As such, management considers the equipment property of the Agency.

#### Investments

The Agency invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the accompanying statements of financial position.

United States Anti-Doping Agency Notes to Financial Statements December 31, 2024 and 2023

#### Note 12. Subsequent Events

Subsequent events have been evaluated through May 19, 2025, which is the date the financial statements were available to be issued.